Abstract 3050
Background
Although surgical resection is the main treatment for rectal cancer, the optimal surgical protocol for elderly patients with rectal cancer remains controversial. Robot-assisted surgery has the following advantages: smaller wounds, less blood loss, quicker recovery, early recovery, and high rate of anal preservation. This study evaluated the feasibility of robot-assisted surgery in elderly patients with rectal cancer.
Methods
This retrospective study enrolled 125 patients aged 28–93 years diagnosed with stage I–III rectal cancer who underwent robot-assisted surgery between May 2013 and April 2018 in a single institution.
Results
In total, 125 patients with rectal cancer, including 100 nonelderly (aged <70 years) and 25 elderly (aged ≥70 years) patients, who underwent robot-assisted surgery were recruited. Between the patient groups, the incidence of overall postoperative complications and postoperative length of hospital stay did not differ significantly (p = 0.930 and 0.095, respectively). No surgical related deaths were noted. The disease-free and overall survival did not differ significantly between the 2 groups (p = 0.610 and 0.298, respectively).
Conclusions
Robot-assisted surgery for rectal cancer is an appropriate approach that is well tolerated in elderly patients, with similar results as for the non-elderly patients. Oncological outcomes, including postoperative complications and survival, did not depend on patient age. Thus, in elderly patients, robot-assisted surgery is a safe and feasible surgical modality for treating operable rectal cancer and leads to age-independent postoperative outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Wei-Chih Su.
Funding
Kaohsiung Medical University Hospital.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2674 - Multicenter Phase I Trial of Trastuzumab Emtansine (T-DM1) in Combination with Non-Pegylated Liposomal Doxorubicin (NPLD) in HER2[+] Metastatic Breast Cancer (MBC). THELMA Study
Presenter: Elena López-Miranda
Session: Poster Display session 2
Resources:
Abstract
1398 - Phase 1 study of liposomal formulation of eribulin (E7389-LF) in patients (pts) with advanced solid tumors: primary results of dose-escalation part
Presenter: Noboru Yamamoto
Session: Poster Display session 2
Resources:
Abstract
5818 - Polo-like Kinase 1 inhibitor onvansertib synergizes with paclitaxel in breast cancer carrying p53 mutation
Presenter: Antonio Giordano
Session: Poster Display session 2
Resources:
Abstract
5927 - Phase 1b study of heat shock protein 90 inhibitor, onalespib in combination with paclitaxel in patients with advanced, triple negative breast cancer (NCT02474173).
Presenter: Robert Wesolowski
Session: Poster Display session 2
Resources:
Abstract
1695 - Impact of pertuzumab and T-DM1 on prognosis of HER2-positive metastatic breast cancer (MBC) and factors affecting their efficacy: results from the AGMT_MBC-Registry
Presenter: Simon Peter Gampenrieder
Session: Poster Display session 2
Resources:
Abstract
1742 - Clinical profile and outcome of HER2 positive breast cancer patients with brain metastases treated with HER2 targeted therapy: Real world experience.
Presenter: Prabhat Bhargava
Session: Poster Display session 2
Resources:
Abstract
1846 - Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer: results of single arm phase IV COMACHI study
Presenter: Norikazu Masuda
Session: Poster Display session 2
Resources:
Abstract
5385 - Anti HER-2 Therapies and Left Ventricular Dysfunction The Renaissance Study
Presenter: ANDRES DANIELE
Session: Poster Display session 2
Resources:
Abstract
3320 - Safety and efficacy of T-DM1 in 128 patients with advanced HER2+ breast cancer: The Royal Marsden experience.
Presenter: Nicolò Battisti
Session: Poster Display session 2
Resources:
Abstract
4540 - Use of trastuzumab emtansine (T-DM1; K) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): challenges in assessing effectiveness of treatment sequencing in the real world (RW)
Presenter: Thibaut Sanglier
Session: Poster Display session 2
Resources:
Abstract